Renaissance Technologies (RenTech)'s VNDA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 3.76 M shares of Vanda Pharmaceuticals Inc. (VNDA) worth $25.98 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in VNDA, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 594,500 shares. Largest reduction occurred in Q4 2022, reducing 405,808 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Vanda Pharmaceuticals (VNDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vanda Pharmaceuticals (VNDA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +378,598 | Add 11.20% | 3.76 M | $6.91 |
| Q4 2025 | -95,964 | Reduce 2.76% | 3.38 M | $8.82 |
| Q3 2025 | +29,465 | Add 0.85% | 3.48 M | $4.99 |
| Q2 2025 | -118,965 | Reduce 3.34% | 3.45 M | $4.72 |
| Q1 2025 | -287,374 | Reduce 7.46% | 3.57 M | $4.59 |
| Q4 2024 | -157,723 | Reduce 3.93% | 3.85 M | $4.79 |
| Q3 2024 | -102,603 | Reduce 2.49% | 4.01 M | $4.69 |
| Q2 2024 | -161,500 | Reduce 3.78% | 4.11 M | $5.65 |
| Q1 2024 | +594,500 | Add 16.15% | 4.28 M | $4.11 |
| Q4 2023 | +415,100 | Add 12.71% | 3.68 M | $4.22 |
| Q3 2023 | +153,958 | Add 4.95% | 3.27 M | $4.32 |
| Q2 2023 | +176,842 | Add 6.02% | 3.11 M | $0.01 |
| Q1 2023 | +45,800 | Add 1.59% | 2.94 M | $0.01 |
| Q4 2022 | -405,808 | Reduce 12.32% | 2.89 M | $0.01 |
| Q3 2022 | -341,200 | Reduce 9.38% | 3.3 M | $9.88 |
| Q2 2022 | +427,819 | Add 13.33% | 3.64 M | $10.90 |
| Q1 2022 | -3,600 | Reduce 0.11% | 3.21 M | $11.31 |
| Q4 2021 | -70,108 | Reduce 2.14% | 3.21 M | $15.69 |
| Q3 2021 | -28,600 | Reduce 0.86% | 3.28 M | $17.14 |
| Q2 2021 | -375,558 | Reduce 10.19% | 3.31 M | $21.51 |
| Q1 2021 | -303,923 | Reduce 7.62% | 3.69 M | $15.02 |
| Q4 2020 | -390,519 | Reduce 8.91% | 3.99 M | $13.14 |
| Q3 2020 | +151,100 | Add 3.57% | 4.38 M | $9.66 |
| Q2 2020 | +380,168 | Add 9.88% | 4.23 M | $11.44 |
| Q1 2020 | +396,542 | Add 11.48% | 3.85 M | $10.36 |
| Q4 2019 | +244,772 | Add 7.63% | 3.45 M | $16.41 |
| Q3 2019 | +410,290 | Add 14.66% | 3.21 M | $13.28 |
| Q2 2019 | +233,300 | Add 9.10% | 2.8 M | $14.09 |
| Q1 2019 | +53,400 | Add 2.13% | 2.56 M | $18.40 |
| Q4 2018 | +462,700 | Add 22.59% | 2.51 M | $26.13 |
| Q3 2018 | +367,400 | Add 21.85% | 2.05 M | $22.95 |
| Q2 2018 | +41,200 | Add 2.51% | 1.68 M | $19.05 |
| Q1 2018 | +205,200 | Add 14.30% | 1.64 M | $16.85 |
| Q4 2017 | +216,600 | Add 17.78% | 1.43 M | $15.20 |
| Q3 2017 | +120,300 | Add 10.96% | 1.22 M | $17.90 |
| Q2 2017 | +158,700 | Add 16.90% | 1.1 M | $16.30 |
| Q1 2017 | +370,900 | Add 65.26% | 939,250 | $14.00 |
| Q4 2016 | +136,300 | Add 31.55% | 568,350 | $15.95 |
| Q3 2016 | +281,000 | Add 186.03% | 432,050 | $16.64 |
| Q2 2016 | -265,850 | Reduce 63.77% | 151,050 | $11.19 |
| Q1 2016 | +79,510 | Add 23.57% | 416,900 | $8.36 |
| Q4 2015 | +337,390 | New Buy | 337,390 | $9.31 |
| Q2 2015 | -195,100 | Sold Out | 0 | $0.00 |
| Q1 2015 | +195,100 | New Buy | 195,100 | $9.30 |
| Q4 2013 | -256,600 | Sold Out | 0 | $0.00 |
| Q3 2013 | -97,529 | Reduce 27.54% | 256,600 | $10.95 |
| Q2 2013 | +354,129 | Add 0.00% | 354,129 | $8.08 |
Renaissance Technologies (RenTech)'s Vanda Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Vanda Pharmaceuticals Inc. (VNDA) in Q2 2013, acquiring 354,129 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Vanda Pharmaceuticals Inc. (VNDA) for 47 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Vanda Pharmaceuticals Inc. (VNDA) was in Q1 2024, adding 4,275,625 shares worth $17.57 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 3,759,559 shares of Vanda Pharmaceuticals Inc. (VNDA), valued at approximately $25.98 M.
As of the Q1 2026 filing, Vanda Pharmaceuticals Inc. (VNDA) represents approximately 0.04% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Vanda Pharmaceuticals Inc. (VNDA) was 4,380,922 shares, as reported at the end of Q3 2020.